CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD EBITDA Margin
EBITDA as a percentage of revenue.
CONMED CorporationNYSE: CNMD
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 12.1%
EBITDA Margin was 12.1% in Q1 FY2026, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 12.4%, down 6.5 pp year over year. Over 3 fiscal years it widened by 10.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 20.0% for the fiscal year ending Dec 2026, up from 11.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 12.1%-2.8 pp QoQ
- Last fiscal yearDec 2025
- 11.2%-9.6 pp YoY
- LTMMar 2026
- 12.4%-6.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.0 pp | +6.0 pp | +3.0 pp |
| 1 year | -9.6 pp | +8.7 pp | +18.3 pp |
| 3 years | +10.5 pp | +7.6 pp | -2.9 pp |
| 5 years | +8.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 11.2%
- Year-over-year change
- -9.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.2% | -9.6pp |
| FY2024 | 2024-12-31 | 20.8% | +5.4pp |
| FY2023 | 2023-12-31 | 15.5% | +14.7pp |
| FY2022 | 2022-12-31 | 0.7% | -17.0pp |
| FY2021 | 2021-12-31 | 17.7% | — |
EBITDA Margin vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 EBITDA Margin of 12.4% is the 4th highest of the 11 companies compared; the peer median is -5.8%.
- Its year-over-year change of -6.5 pp is the 6th highest of 11, against a peer median of -4.1 pp.
- Over three fiscal years its change of +10.5 pp compares with a peer median of -0.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 27.5% | -8.4 pp | -14.5 pp | |
| LTM Jun 2026 | 18.4% | -0.8 pp | -0.5 pp | |
| LTM Apr 2026 | 16.2% | -7.4 pp | -5.7 pp | |
| LTM Mar 2026 | 12.4% | -6.5 pp | +10.5 pp | |
| LTM Aug 2026 | 11.9% | +111.0 pp | +3.8 pp | |
| LTM Sep 2026 | -4.0% | +21.1 pp | +24.5 pp | |
| LTM Mar 2026 | -7.7% | +82.2 pp | +350.1 pp | |
| LTM Sep 2026 | -15.2% | -24.8 pp | -32.6 pp | |
| LTM Mar 2026 | -23.0% | -10.7 pp | -5.5 pp | |
| LTM Jan 2026 | -152.9% | -23.0 pp | — | |
| LTM Mar 2026 | -581.9% | +549.6 pp | +308.9 pp | |
| Peer median (excluding CNMD) | -5.8% | -4.1 pp | -0.5 pp | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.01B | 1.05B | 1.24B | 1.31B | 1.37B |
| Cost of Revenue | 442.6M | 474.23M | 568.5M | 573.98M | 649.12M |
| Gross Profit | 568.04M | 571.25M | 676.25M | 733.03M | 725.38M |
| Gross Margin | 56.2% | 54.6% | 54.3% | 56.1% | 52.8% |
| Research & Development | 43.57M | 47.15M | 52.6M | 54.43M | 55.88M |
| Selling, General & Admin | 414.75M | 454.04M | 503.04M | 478.28M | 528.36M |
| Operating Expenses | 458.32M | 501.19M | 555.64M | 532.71M | 584.24M |
| Depreciation & Amortization | 70.74M | 49.76M | 71.87M | 71.86M | 52.34M |
| EBITDA | 179.33M | 7.8M | 192.48M | 272.18M | 154.55M |
| EBITDA Margin | 17.7% | 0.7% | 15.5% | 20.8% | 11.2% |
| Operating Income | 109.72M | 70.05M | 120.6M | 200.33M | 141.13M |
| Operating Margin | 10.9% | 6.7% | 9.7% | 15.3% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 35.49M | 28.91M | 39.78M | 37.3M | 31.09M |
| Other Income / Expenses | (36.61M) | (140.92M) | (39.78M) | (37.3M) | (70.01M) |
| Income Before Tax | 73.11M | (70.86M) | 80.83M | 163.03M | 71.12M |
| Pre-Tax Margin | 7.2% | -6.8% | 6.5% | 12.5% | 5.2% |
| Income Tax Expense | 10.56M | 9.72M | 16.37M | 30.61M | 24.06M |
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Net Margin | 6.2% | -7.7% | 5.2% | 10.1% | 3.4% |
| EPS (Basic) | 2.14 | (2.68) | 2.10 | 4.29 | 1.52 |
| EPS (Diluted) | 1.94 | (2.68) | 2.04 | 4.26 | 1.51 |
| Weighted Avg Shares | 29.16M | 30.04M | 30.67M | 30.85M | 31.04M |
| Weighted Avg Shares (Diluted) | 32.22M | 30.04M | 31.55M | 31.11M | 31.15M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.